Ensysce Biosciences Inc Financial Flexibility Index
Ensysce Biosciences Inc financial flexibility index. Ensysce Biosciences Inc (ENSC) has a Financial Flexibility Index of -0.48x as of June 2026. Free cash flow of $-1.96 Million (operating CF $-1.96 Million minus capex $0.00) represents 0% of total liabilities ($4.07 Million). See ENSC free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of Ensysce Biosciences Inc (2017–2025)
Financial flexibility index of Ensysce Biosciences Inc from 2017 to 2025. Historical Financial Flexibility Index trend for Ensysce Biosciences Inc across 9 annual periods. Check ENSC operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Ensysce Biosciences Inc Financial Flexibility Index by Year (2017–2025)
Ensysce Biosciences Inc financial flexibility index by year from 2017 to 2025. Year-by-year free cash flow to debt coverage for Ensysce Biosciences Inc. For the full cash flow conversion analysis, see Ensysce Biosciences Inc (ENSC) cash flow conversion.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -1.68x | $-7.68 Million | $-7.81 Million | $4.57 Million | ▲ +50.3% |
| 2024 | -3.38x | $-7.50 Million | $-7.50 Million | $2.22 Million | ▼ -5.4% |
| 2023 | -3.21x | $-10.78 Million | $-10.78 Million | $3.36 Million | ▼ -77.9% |
| 2022 | -1.80x | $-17.89 Million | $-17.89 Million | $9.91 Million | ▼ -437.9% |
| 2021 | -0.34x | $-8.24 Million | $-8.24 Million | $24.58 Million | ▼ -88.5% |
| 2020 | -0.18x | $-1.25 Million | $-1.25 Million | $7.01 Million | ▼ -116.7% |
| 2019 | 1.06x | $10.99 Million | $10.99 Million | $10.34 Million | ▲ +739.0% |
| 2018 | -0.17x | $-1.24 Million | $-1.24 Million | $7.44 Million | ▼ -373.0% |
| 2017 | -0.04x | $-251.83K | $-251.83K | $7.16 Million | — |